ATOSSA THERAPEUTICS, INC. — Form 8-K

Atossa Therapeutics presented a corporate strategy for (Z)-Endoxifen, an oral SERM/SERD molecule, targeting three disease areas: ER+ breast cancer (EVANGELINE Phase 2 enrollment completed; I-SPY2 combinations partnered with abemaciclib and elagolix); McCune-Albright Syndrome (MAS) with Rare Pediatric Disease designation and IND clearance anticipated 2H26; and Duchenne Muscular Dystrophy (DMD) with RPD and ODD designations, IND clearance anticipated 2H26, Phase 2 initiation 1H27. As of June 30, 2026, the company held $26.1M cash with no debt, plus up to $12M from warrant exercises. The presentation discloses ~800 patients dosed to date with (Z)-Endoxifen and potential PRV eligibility upon marketing approval in rare diseases (PRV market range $100–$220M from recent transactions).